Sage Journals: Discover world-class research

Abstract

Myocardial infarction (MI) is a serious cardiovascular disease resulting in high rates of morbidity and mortality. Although advances have been made in restoring myocardial perfusion in ischemic areas, decreases in cardiomyocyte death and infarct size are still limited, attributing to myocardial ischemia/reperfusion (I/R) injury. It is necessary to develop therapies to restrict myocardial I/R injury and protect cardiomyocytes against further damage after MI. Many studies have suggested that peroxisome proliferator-activated receptor γ (PPARγ), a ligand-inducible nuclear receptor that predominantly regulates glucose and lipid metabolism, is a promising therapeutic target for ameliorating myocardial I/R injury. Thus, this review focuses on the role of PPARγ in cardioprotection during myocardial I/R. The cardioprotective effects of PPARγ, including attenuating oxidative stress, inhibiting inflammatory responses, improving glucose and lipid metabolism, and antagonizing apoptosis, are described. Additionally, the underlying mechanisms of cardioprotective effects of PPARγ, such as regulating the expression of target genes, influencing other transcription factors, and modulating kinase signaling pathways, are further discussed.

Keywords

myocardial ischemia/reperfusion injury peroxisome proliferator-activated receptor γ cardioprotection mechanisms

Introduction

Myocardial infarction, one of the most serious cardiovascular diseases, causes a serious threat to human health and results in high rates of morbidity and mortality.¹ Although it is important to salvage viable myocardium by emergent restoration of myocardial perfusion in ischemic areas, reperfusion itself can trigger complex pathophysiological processes and even exacerbate the injury initially induced by ischemia, termed myocardial ischemia/reperfusion (I/R) injury.² Reperfusion injury has been shown to extend the infarct size and cause myocardial dysfunction, such as myocardial stunning, arrhythmias, heart failure, and even cardiac arrest.^3,4

Fortunately, recent studies involving myocardial I/R injury and cardiac protection show encouraging developments. Peroxisome proliferator-activated receptor γ (PPARγ), a ligand-inducible nuclear receptor belonging to the nuclear transcription factor superfamily,⁵ is a representative example. Accumulating studies demonstrate that PPARγ can protect cardiomyocytes against I/R injury through regulating cardiac oxidative stress,^6
–8 inflammatory responses,^9
–11 glucose and lipid metabolism,^12
–14 and apoptosis.^15
–17 With respect to the underlying mechanisms, PPARγ plays an essential role in regulating gene expression (eg, glucose transporter-4 [GLUT-4],^12,13 adiponectin,¹⁸ and nuclear factor κ B inhibitor α [IκBα]¹⁹), influencing transcription factors (eg, nuclear factor κ B [NF-κB]²⁰), and modulating kinase signaling pathways (eg, protein kinase B [AKT],^12,21 c-Jun N-terminal kinase [JNK],¹⁵ and extracellular signal-regulated kinase [ERK]²²).

In this review, briefly pathophysiological mechanisms of myocardial I/R injury, especially those influenced by PPARγ, will be firstly described. Subsequently, characteristics, ligands, and general function of PPARγ will be discussed to show an overview of PPARγ. Most importantly, cardioprotective effects of PPARγ against I/R injury and underlying PPARγ-mediated mechanisms will be discussed in detail.

Mechanisms of Myocardial I/R Injury

Since myocardial I/R injury is one of the important obstacles to decrease cardiomyocyte death and infarct size after restored myocardial perfusion,²³ mechanisms of myocardial I/R injury have been studied and elucidated in detail. In this respect, excessive oxidative stress is regarded as one of the primary causes of myocardial I/R injury.²⁴ When oxidases (eg, inducible nitric oxide [NO] synthase and nicotinamide adenine dinucleotide phosphate [NADPH] oxidase) are uncontrollably activated accompanied by mitochondrial dysfunction,^25
–27 reactive oxygen species (ROS; eg, NO and hydrogen peroxide [H₂O₂]) are generated in excess, enhancing oxidative stress during reperfusion.²⁴

Additionally, oxidative stress is also increased associated with abnormal myocardial inflammatory responses,²⁸ which is another important reason contributing to myocardial I/R injury.²⁹ In pathophysiological progression of abnormal myocardial inflammatory responses, NF-κB signaling pathway plays an essential role in promoting the expression of multiple pro-inflammatory factors and leukocyte adhesion molecules.^10,30,31 Along with these factors, individually or interactively, inflammatory cells infiltrate in reperfusion areas, thereby increasing tissue vulnerability and causing further damage.^10,32 Additionally, infiltration of inflammatory cells also leads to endothelial dysfunction, which is accompanied by decreased expression and coupling of endothelial NO synthase (eNOS), subsequently aggravating myocardial I/R injury.^33,34

Cardiac metabolic dysfunction of glucose and lipid, which is associated with dysfunction of GLUT-4 expression and translocation, is also an important reason, exacerbating myocardial I/R injury.^13,35 On the one hand, dysfunction of glucose uptake and utilization reduces production of adenosine triphosphate, thereby exacerbating cardiomyocyte energy crisis.¹³ On the other hand, as fatty acid (FA) oxidation relies on normal glucose metabolism,³⁶ dysfunction of glucose metabolism results in abnormal lipid metabolism, which promotes ROS generation and contributes to deleterious effects on cardiomyocytes.^36
–38 In addition to metabolic dysfunction, cardiomyocyte apoptosis, which is associated with quantitative disorders of apoptosis-related proteins^39,40 and mitochondria dysfunction induced by calcium paradox,^41,42 also aggravates myocardial I/R injury.

An Overview of PPARγ

Peroxisome Proliferator-Activated Receptor γ as a Nuclear Receptor

Peroxisome proliferator-activated receptor γ is an isoform of PPARs, which are ligand-inducible nuclear receptors belonging to the nuclear transcription factor superfamily. The other 2 isoforms of PPARs are PPARα and PPARβ/δ.⁴³ With respect to the distributions of PPARs, PPARα is predominantly expressed in liver, heart, kidney cortex, and skeletal muscle.⁴⁴ Peroxisome proliferator-activated receptor β/δ is ubiquitous,⁴⁵ whereas PPARγ is predominantly expressed in adipose tissue and macrophages, as well as in hepatocytes, cardiomyocytes, kidney, and skeletal muscle.⁴⁶

Evidence from previous studies has suggested that there are 2 detected proteins, PPARγ1 and PPARγ2, which are principally encoded by 4 messenger RNAs (mRNAs) including PPARγ1, PPARγ2, PPARγ3, and PPARγ4.⁴⁷ The mRNAs of PPARγ1, PPARγ3, and PPARγ4 encode the same PPARγ1 proteins,^48,49 whereas the mRNA of PPARγ2 encodes PPARγ2 proteins.⁴⁸ With respect to PPARγ transcription, PPARγ1 mRNA is found in almost all tissues at varying levels, while PPARγ2 mRNA is predominantly found in adipose tissue.⁵⁰ Peroxisome proliferator-activated receptor γ3 mRNA is distributed in macrophages, adipose tissue, and T lymphocyte, whereas PPARγ4 distribution has not been fully elucidated.^49,51

Under diseased conditions, the expression of PPARγ in heart changes to some degree. It has been observed that decreased cardiac expression of PPARγ is associated with diet-induced obesity,⁵² while the expression of PPARγ is increased accompanied by decreased expression of PPARα in cardiomyocytes under diabetes mellitus.⁵³ Moreover, after myocardial ischemia, the expression of PPARγ is upregulated, whereas the expression of PPARα and PPARβ/δ is not altered in the infarcted areas.⁵⁴

Peroxisome proliferator-activated receptor γ is activated by ligands to execute its biological effects. These effects, involving oxidative stress, inflammatory responses, glucose and lipid metabolism, and cellular apoptosis, are summarized in Table 1 and will be hereinafter described in detail.

Table 1.

Effects of PPARγ Against Myocardial I/R Injury.

	Module	Treatment	Effects	References
Oxidative stress	Rat coronary artery smooth muscle cells	PIO (10 μM for 2 days)	NADPH oxidase activity↓, ROS production↓, NF-κB activation↓, oxidative stress↓	⁶
	C57BL/6J mice or CBA/J mice	PIO (3 mg/kg/d for 1 day, orally)	PMN migration↓, SOD activity↑, NADPH oxidase activity↓, oxidative stress↓	⁵⁵
	T2DM mice	RSG (3 mg/kg/d for 7 days, orally)	NADPH oxidase activity↓, oxidative stress↓	⁵⁶
Inflammation	Human vein endothelial cells	PIO (25 μM for 1 day) or RSG (5 μM for 1 day)	IκBα expression↑, NF-κB activation↓, eNOS expression↑, inflammatory response↓	¹⁹
	Zucker diabetic fatty rats	Telmisartan (7-12 mg/kg/d for 3 weeks, orally)	Adiponectin expression↑, NF-κB expression↓, TLR expression↓, TNF-α expression↓, inflammatory response↓	¹⁸
	New Zealand white rabbits	PIO (1 mg/kg/d for 7 days, orally)	AKT↑, eNOS↑, microvascular dysfunction↓	⁵⁷
	C57BL/6J mice	Irbesartan (3 mg/kg, intravenously)	MCP-1↓, monocyte infiltration↓, inflammatory response↓	¹⁰
	New Zealand white rabbits	Telmisartan (5 mg/kg/d for 14 days, orally)	NF-κB expression↓, ICAM-1 and VCAM-1 levels↓, leukocyte infiltration↓, microvascular dysfunction↓	⁵⁸
Glucose and lipid metabolism	Dogs	RSG (1 mg/kg in cardioplegic solution)	GLUT-4 expression↑, glucose and lipid metabolism↑	¹³
	FVB/NJ mice	RSG (1 mg/kg, intravenously)	JNK activation↓, AMPK and AKT activation↑, GLUT-4 translocation↑, infarct size↓	¹²
	Zucker diabetic fatty rats	RSG (3 mg/kg/d for 8 days, orally)	AKT activation↑, GLUT-4 and glycogen synthase kinase-3 expression↑, glucose uptake↑	¹⁴
Apoptosis	Sprague-Dawley rats	PIO (5 and 10/kg/d for 7 days, orally)	ERK activation↑, COX-2 expression↑, apoptosis↓, infarct size↓	²²
	Rat cardiomyocytes	RSG (1 μM for 1 hour)	H₂O₂-induced oxidative stress↓, caspase-3 activity↓, p53 activity↓, H₂O₂-induced apoptosis↓	⁸
	Otsuka Long-Evans Tokushima fatty rats	PIO (10 mg/kg/d for 4 weeks, orally)	AKT activation↑, heat shock protein 72 expression↑, apoptosis↓	¹⁶

Abbreviations: AKT, protein kinase B; AMPK, 5’-adenosine monophosphate-activated protein kinase; COX-2, cyclooxygenase-2; eNOS, endothelial nitric oxide synthase; ERK, extracellular signal–regulated kinase; GLUT-4, glucose transporter type 4; H₂O₂, hydrogen peroxide; ICAM-1, intercellular adhesion molecule-1; I/R, ischemia/reperfusion; IκBα, nuclear factor κ B inhibitor α; JNK, c-Jun NH2-terminal kinase; MCP-1, monocyte chemotactic protein-1; NADPH, nicotinamide adenine dinucleotide phosphate; NF-κB, nuclear factor κ B; p53, protein 53; PPARγ, peroxisome proliferator-activated receptor γ; PIO, pioglitazone; PMN, polymorphonuclear leukocyte; ROS, reactive oxygen species; RSG, rosiglitazone; SOD, superoxide dismutase; TLR, Toll-like receptor; TNF-α, tumor necrosis factor α; T2DM, type 2 diabetic mellitus; VCAM-1, vascular cell adhesion molecule-1.

The Ligands of PPARγ

The ligands of PPARγ are divided into endogenous ligands and synthetic ligands.⁵⁹ Endogenous ligands principally include FA metabolites and their derivatives such as eicosanoids (eg, prostaglandins, 12-, and 15-hydroxyeicosatetraenoic acid) and conjugated linoleic acids (eg, 9- and 13-hydroxyoctadecadienoic acid).^59,60 Particularly, a prostaglandin, 15-deoxy-Δ^12,14-prostaglandin J2 (15d-PGJ2) is regarded as a representative endogenous ligand of PPARγ. Interestingly, the level of 15d-PGJ2 in cardiac tissues is increased after myocardial I/R, which is related to the activation of cyclooxygenase 2 (COX-2).¹¹

As for synthetic ligands, thiazolidinediones (TZDs), well-known antidiabetic drugs, are typical synthetic ligands of PPARγ.⁴⁴ Rosiglitazone (RSG) and pioglitazone (PIO) are 2 representative TZDs, which are commonly used and have potent effects on activating PPARγ, whereas other TZDs, including ciglitazone and troglitazone, are lesser used.^44,61 Moreover, several angiotensin receptor blockers, including telmisartan⁶² and irbesartan,⁶³ are demonstrated to be partial agonists of PPARγ receptors, while dual PPARs agonists including dual PPARα/γ agonists (eg, aleglitazar²¹ and GCP-02⁶⁴), dual PPARδ/γ agonists (eg, compound 23 and compound 20⁶⁵), and dual PPARα/δ agonists (eg, T0913659⁶⁶) can correspondingly activate 2 isoforms of PPARs.⁶⁶ Furthermore, there are emerging pan PPARs agonists (eg, bezafibrate^67,68 and chiglitazar⁶⁹), simultaneously activating all 3 isoforms and resulting in combined effects of PPARs.

Notably, although plenty of PPARγ ligands induce their responses by binding with PPARγ, some PPARγ ligands, including 15d-PGJ2 and TZDs, can also induce their biological effects through additional PPARγ-independent mechanisms.^8,11,70 These mechanisms, such as directly modulating kinase activity⁷⁰ and regulating gene transcription,^8,11 will be discussed in following sections.

Transcriptional Transactivation of PPARγ

Upon binding with endogenous or synthetic ligands, PPARγ is activated and translocates into the nucleus, thereby interacting with the retinoid X receptor (RXR) and forming a heterodimeric complex. The resulting PPARγ–RXR complex subsequently recruits coactivators, such as PPARγ coactivator-1α⁵, and binds to peroxisome proliferator-responsive elements (PPREs).^5,71 As the result of it, the productions encoded by PPARγ target genes, including those involving in lipid store, glucose metabolism (eg, adiponectin¹⁸ and GLUT-4¹³), oxidative stress (eg, manganese superoxide dismutase⁷²), and inflammatory responses (eg, IκBα¹⁹), are significantly increased, which subsequently contributes to modulating cells survival.⁷¹

Transcriptional Transrepression of PPARγ

In addition to transactivation, the activated PPARγ with endogenous or synthetic ligands can also negatively modulate relevant gene expression by directly inhibiting other transcription factors or competing with other transcription factors for coactivators, termed transcriptional transrepression, which is independent from PPREs.^5,73

A representative example is the NF-κB signaling pathway mediated by PPARγ. When NF-κB signaling pathway is resting, NF-κB is a tetramer including subunit p50, subunit p65, IκBα, and IκBβ.³¹ When IκBα and IκBβ are disassociated from the tetramer associated with stimulation of pro-inflammatory factors,⁷⁴ the p50/p65 dimer is activated, recruiting their coactivators and subsequently forming a new complex. The new complex can bind to NF-κB-specific promoter sequences and induce the expression of other inflammatory factors (eg, tumor necrosis factor α, interleukin-1 [IL-1], interleukin-6 [IL-6], intercellular adhesion molecule-1 [ICAM-1], and vascular cell adhesion molecule-1 [VCAM-1]), which can promote inflammatory responses.^58,75,76

Activated PPARγ with endogenous or synthetic ligands can not only directly combine with the p50/p65 dimer and form a new complex that downregulates the NF-κB signaling pathway^20,77 but also upregulate the expression of IκBα and indirectly inhibit the transcriptional activity of NF-κb.¹⁹ Additionally, the activator protein-1 signaling pathway and the Janus kinase/signal transducer and activator of transcription signaling pathway are also inhibited by activated PPARγ through similar ways mentioned above.^5,78

Complementary Effects and Interactions Between PPARs

Combined activation of PPARs is believed to contribute to complementary and synergistic effects, especially those on energy metabolism.⁶⁶ Primarily, PPARα promotes FA uptake and β-oxidation,⁷⁹ whereas PPARγ promotes glucose metabolism, FA uptake, and storage but lightly FA oxidation.⁸⁰ Peroxisome proliferator-activated receptor β/δ, which is an emerging isoform of PPARs, contributes to improving FA β-oxidation and glucose oxidation.⁸¹ Since all 3 isoforms of PPARs involve in modulating glucose and lipid metabolism, combined activation of PPARs can induce not only more effective promotion but also better counterbalance on energy metabolism.^64,66,68,82

Apart from metabolic effects, PPARs further exhibit nonmetabolic effects on anti-inflammation and antioxidation. Specially, PPARγ and PPARα can synergistically interact with the NF-κB signaling pathway and contribute to combined repression on inflammatory responses.^20,83 Besides, combined effects of PPARs on mediating kinase activity (eg, AKT,²¹ 5’-adenosine monophosphate-activated protein kinase [AMPK]⁸⁴) also play important roles in mediating inflammation and ameliorating I/R injury.^21,84

Additionally, interactions between PPARγ and other 2 PPAR isoforms have caused extensive concern. Since PPARβ/δ is a special PPAR isoform, which recruits corepressors and represses PPREs-mediated transcription when bound to DNA, PPARβ/δ has been shown to contribute to inhibiting PPARγ-mediated transcription.⁸⁵ Moreover, a similar suppressive effect of PPARβ/δ is also attributed to the competition for RXR between PPARγ and PPARβ/δ, which inhibits the form of PPARγ–RXR complex.⁸⁶ In contrast, pharmacological activation of PPARα has been shown to associate with promotive PPARγ-mediated transcription through upregulating the expression of PPARγ coactivator-1α.⁸⁷ These interactions between PPARγ and other PPAR isoforms allow for fine tuning of PPARγ signaling pathway and contribute to harmonizing efficacy and side effects of PPARγ.⁸⁸

Peroxisome Proliferator-Activated Receptor γ in Cardioprotection

Peroxisome Proliferator-Activated Receptor γ and Oxidative Stress

As discussed above, excessive oxidative stress, which is principally attributable to excessive ROS generation, is a key reason of aggravated myocardial I/R injury.^24
–26 Inhibition of ROS production potentially alleviates oxidative stress during myocardial reperfusion. In fact, accumulating studies have indicated that the production of ROS can be inhibited through PPARγ-mediated mechanisms. For instance, a recent study demonstrated that PIO (10 μM for 2 days) protected coronary artery smooth muscle cells against excessive oxidative stress by suppressing NADPH oxidase and ROS generation through a PPARγ-dependent mechanism.⁶ Interestingly, a similar outcome was observed in murine heterotopic cardiac allotransplantation models, which pretreated with PIO (3 mg/kg/d for 1 day, orally, in mice) before cardiac transplantation and had less graft oxidant stress due to PPARγ-mediated suppression on NADPH oxidase.⁵⁵ Similarly, antioxidant effects of RSG in cardiac tissues have been observed. Kim et al reported that detrimental effects of H₂O₂-induced oxidative stress were limited through activation of PPARγ with RSG (1 μM for 1 hour, in rat cardiomyocytes).⁸ Meanwhile, RSG upregulated thioredoxin expression in rat cardiomyocytes through an additional PPARγ-independent mechanism, thereby suppressing intracellular ROS generation and resulting in a combined effect on decreasing oxidative stress.⁸ Through a PPARγ-independent mechanism, RSG (20 μM for 2 days, in human endothelial cells) directly activated AMPK and subsequently inhibited NADPH oxidase.⁷⁰ More importantly, apart from its antioxidant effects in healthy models, activated PPARγ by RSG (3 mg/kg/d for 7 days, orally) has further been shown to protect coronary arteriolar against NADPH oxidase-induced oxidative stress in type 2 diabetic mice.⁵⁶

Notably, antioxidant effects of activated PPARγ are further reported in some human trials. A clinical trial involving in 306 patients who underwent coronary artery bypass grafting has suggested that activated PPARγ upregulated adiponectin gene expression and subsequently decreased NADPH oxidase-mediated oxidative stress in heart tissue.⁷ Interestingly, in this clinical trial, the activation of PPARγ was attributed to oxidation-induced 4-hydroxynonenal, a precursor of 13-hydroxyoctadecadienoic acid,⁸⁹ suggesting that physiological activation of PPARγ also protects heart tissue against excessive oxidative stress during I/R.⁷

Peroxisome Proliferator-Activated Receptor γ and Inflammatory Responses

Since the NF-κB signaling pathway is generally recognized as one of the key mechanisms of myocardial inflammatory responses during I/R,³¹ studies exploring the relationship between PPARγ and NF-κB have been performed. A recent study revealed the pivotal and irreplaceable role of PPARγ in inhibition on NF-κB activity through demonstrating that PPARγ-knockout mice had more increased NF-κB activity and more enhanced inflammatory responses in cardiomyocytes, compared with wild mice.⁷⁶

In contrast, activated by ciglitazone (5 mg/kg, intraperitoneally, in rats), PPARγ has been reported to suppress NF-κB activity,¹¹ which ameliorated myocardial inflammatory responses (Figure 1).^18,11 Through a similar PPARγ/NF-κB pathway, irbesartan (3.0 mg/kg, intravenously, in mice) has resulted in increased inhibition on monocyte chemotactic protein-1 (MCP-1) and attenuated accumulation of inflammatory monocytes in risky reperfusion areas.¹⁰ More importantly, in a human trial involving in 319 patients with type 2 diabetic mellitus (T2DM), treatment with PIO (15 mg) has contributed to less myocardial I/R injury, possibly attributed to the suppression on inflammatory responses.⁹

Figure 1.

The underlying molecular mechanisms of PPARγ in cardioprotection. Upon binding with endogenous or synthetic ligands, PPARγ is activated. Activation of PPARγ attenuates the activity of JNK, thereby suppressing apoptosis by upregulating BCL-2 and suppressing caspase-3. In contrary, activated PPARγ enhances the activity of ERK, AMPK, and AKT. Activated ERK improves the activity of COX-2 and suppresses the expression of BAD and BAX, subsequently promoting antiapoptotic effects. As AMPK is activated in both PPARγ-dependent and PPARγ-independent manners, the expression of Glut-4 is upregulated contributing to ameliorated glucose metabolism, while the activity of NADPH oxidase is inhibited, resulting in attenuated oxidative stress. Associated with activated AKT, eNOS activity is enhanced and results in increased bioavailability of NO and ameliorated microvascular dysfunction, while the expression of GLUT-4 and HSP-72 is upregulated, respectively, contributing to ameliorated glucose metabolism and suppressed apoptosis. Furthermore, activated PPARγ can directly inhibits NF-κB and subsequently downregulates the expression of pro-inflammation cytokines (eg, IL-1, IL-6, and MPC-1) and leukocyte adhesion molecules (eg, ICAM-1 and VCAM-1), contributing to decreased inflammatory responses and ameliorated microvascular dysfunction. Upon binding with RXR, activated PPARγ can upregulate the expression of target genes, including IκBα and adiponectin. IκBα has been shown to inhibit NF-κB activity, whereas induced adiponectin can inhibit excessive cytosolic Ca²⁺, which promotes the mitochondria-dependent apoptosis and downregulates the expression of TLR, subsequently inhibiting TNF-α which can promote apoptosis and upregulate the expression of pro-inflammation cytokines including IL-1 and IL-6. Moreover, associated with upregulated adiponectin, AMPK activity is enhanced, whereas the activity of NADPH oxidase is suppressed and subsequently results in attenuated oxidative stress. AMPK indicates 5’-adenosine monophosphate-activated protein kinase; AKT, protein kinase B; BAD, BCL-2/BCL-XL-associated death promoter; BAX, BCL-2 associated X protein; BCL-2, B cell leukemia/lymphoma 2; COX-2, cyclooxygenase-2; eNOS, endothelial nitric oxide synthase; ERK, extracellular signal-regulated kinase; GLUT-4, glucose transporter-4; HSP-72, heat shock protein 72; ICAM-1, intercellular adhesion molecule-1; IL, interleukin; IκBα, nuclear factor κ B inhibitor α; JNK, c-Jun N-terminal kinase; MCP-1, monocyte chemotactic protein-1; NADPH, nicotinamide adenine dinucleotide phosphate; NF-κB, nuclear factor κ B; NO, nitric oxide; PPARγ, peroxisome proliferator-activated receptor γ; RXR, retinoid X receptor; TNF-α, tumor necrosis factor α; TLR, Toll-like receptor; VCAM-1, vascular cell adhesion molecule-1.

Furthermore, adiponectin is increasingly regarded as a mediator between PPARγ and inflammatory responses because of its ability on modulating inflammatory signaling pathways. Induced by PPARγ with telmisartan (7-12 mg/kg/d for 3 weeks, orally, in diabetic rats), adiponectin downregulated the expression of Toll-like receptors, thereby suppressing the expression of TNF-α and NF-κB.¹⁸ Suppressed TNF-α contributes to downregulation of the expression of other inflammatory cytokines including IL-1 and IL-6,⁹⁰ while inhibited NF-κB is responsible for downregulating the expression of MCP-1, IL-1, and IL-6, both resulting in attenuated inflammatory responses (Figure 1).^10,76

Numerous reports suggest that cardiac microvascular dysfunction, which is associated with inflammatory responses during I/R,⁹¹ is limited through PPARγ/adiponectin-mediated mechanisms.^34,57,58 As shown by Margaritis et al, PPARγ-induced adiponectin restored eNOS coupling in microvascular endothelial cells, which ameliorated the dysfunction of NO generation and release, and subsequently ameliorated microvascular dysfunction (Figure 1).³⁴ Similarly, PIO (1 mg/kg/d for 7 days, orally, in rabbits) has been shown to drive the PPARγ/AKT pathway and subsequently contribute to the restoration of eNOS in cardiac tissues after I/R.⁵⁷ Moreover, it was reported that telmisartan (5 mg/kg/d for 14 days, orally, in rabbits) downregulated the expression of leukocyte adhesion molecules including ICAM-1 and VCAM-1 in cardiac microvascular endothelial cells through a PPARγ/NF-κB-dependent mechanism (Figure 1).⁵⁸ Attributed to decreased expression of leukocyte adhesion molecules, leukocyte adhesion and infiltration are attenuated, subsequently contributing to ameliorative microvascular dysfunction and decreased inflammatory responses during myocardial I/R.^58,91

Notably, aleglitazar (150-600 nM for 1 day, in human cardiomyocytes), a dual PPARα/γ agonist, has shown additive effects on improving microvascular dysfunction and suppressing apoptosis, attributed to the stimulations of both PPARα/AKT/eNOS and PPARγ/AKT/eNOS signaling pathways.²¹ Similarly, after treatment with bezafibrate (400 mg/kg/d for 21 days, orally, in type I diabetic rats), a pan PPAR agonist, myocardial angiogenesis was improved, which was attributed to combined activation of PPARs and responsible for protecting heart against ischemia injury.⁶⁷

Peroxisome Proliferator-Activated Receptor γ and Cardiac Glucose and Lipid Metabolism

Since decreased expression of GLUT-4 in cardiomyocyte has been shown to contribute to aggravated cardiac glucose and lipid metabolic dysfunction during I/R,³⁵ enhanced GLUT-4 expression possibly improves cardiac metabolism and subsequently ameliorates myocardial I/R injury.^92
–94 In fact, Zhang and Tang, who investigated small interfering RNA-mediated PPARγ gene knockdown in rats, demonstrated that cardiac metabolic dysfunction of glucose and lipid could be induced by PPARγ deficiency.⁹⁵ Conversely, another recent study has indicated that acute treatment with RSG (1 mg/kg) increased the expression of GLUT-4 and enhanced glucose uptake and utilization in dog hearts through a PPARγ-dependent mechanism.¹³ Interestingly, the similar effect of acute treatment with RSG (1 mg/kg, intravenously, in mice) on increased expression of GLUT-4 was also associated with both PPARγ/AMPK and PPARγ/AKT pathways (Figure 1).¹² Consequently, the increased expression of GLUT-4 in heart improves myocardial glucose metabolism, which is further responsible for ameliorated energy crisis, decreased abnormal lipid metabolism production, suppressed ROS generation, and inhibited apoptosis, subsequently attenuating myocardial I/R injury.^37,38,94,96

Moreover, similar beneficial metabolic effects of PPARγ during myocardial I/R have further been demonstrated in both diabetic animal models and humans. As shown by Yue et al, short-term treatment with RSG (3 mg/kg/d for 8 days, orally) contributed to increased expression of glycogen synthase kinase-3 and GLUT-4 and subsequently improved cardiac glucose uptake and utilization in diabetic rats through a PPARγ/AKT pathway.¹⁴ Similarly, in a human trial involving in 51 patients with T2DM and coronary artery disease, short-term treatment with RSG (4-8 mg, for 16 weeks) has shown to decrease circulating lactate concentrations, which indicates the improvement of myocardial glucose and lipid uptake and utilization.⁹⁷ These improvements of myocardial energy metabolism consequently contribute to better cardiomyocyte survival with less reperfusion injury.

However, activation of PPARγ by synthetic ligands, especially long-term activation, has shown to contribute to excessive lipid accumulation in cardiomyocyte, attributed to the promotion of PPARγ on FA uptake and triglyceride storage, but weakly promotion on utilization of FA and triglyceride.^53,98 Subsequently, because of the imbalance between lipid storage and utilization, abnormal lipid intermediates accumulate and lead to cardiomyocyte dysfunction or death, which diminishes the beneficial metabolic effects of PPARγ⁹⁹ and at least in part contributes to some cardiac negative outcomes (eg, cardiac hypertrophy) of treatment with some PPARγ synthetic ligands.^53,99,100

Notably, since activated PPARα is elementary in stimulating lipid consumption through enhancing FA oxidation, the dual or pan agonists of PPARs theoretically harmonize lipid store effects and beneficial metabolic effects of PPARγ in cardiac tissues.^64,66 In fact, in a study involving diet-induced diabetic rats, treatment with bezafibrate (30 mg/kg/d for 6-8 weeks, orally) has been demonstrated to result in both decreased triglycerides store and improved glucose metabolism in cardiac tissues, attributed to its combined effects on activating both PPARα and PPARγ.⁶⁸ Furthermore, bezafibrate lowered the 30-day rehospitalization rates and crude 1-year mortality of patients after acute coronary syndromes, supporting the effects of pan PPAR agonists against myocardial reperfusion injury.⁸²

Thus, it is thought that short-term treatment with PPARγ agonists is beneficial to improve cardiac glucose and lipid metabolism during I/R, whereas long-term treatment with PPARγ agonists potentially contributes to imbalanced cardiac lipid metabolism and diminishes the beneficial cardioprotective effects of PPARγ. Through combined activation of PPARs, emerging pan PPAR agonists are promising to harmonize cardioprotective effects and related metabolic disorders of activation of PPARγ.

Peroxisome Proliferator-Activated Receptor γ and Cardiac Apoptosis

During myocardial reperfusion, the pivotal role of apoptosis in myocardial I/R injury has been frequently observed. Accumulating evidence demonstrate that myocardial I/R injury is limited by inhibiting cardiomyocyte apoptosis through PPARγ-dependent mechanisms.

On one hand, perfusion with RSG (1 μM) in isolated rat hearts before I/R has been reported to activate PPARγ, which subsequently inhibited JNK activity.¹⁵ As activated JNK can aggravate apoptosis by inhibiting B cell leukemia/lymphoma 2 and stimulating caspase-3, the inhibition of JNK attenuates cardiomyocyte apoptosis (Figure 1).^101,102 Additionally, activation of PPARγ with PIO (10 mg/kg/d for 4 weeks, orally, in rats) further resulted in upregulated expression of heat shock protein 72, which protected cardiomyocyte against caspase-dependent apoptosis, through the PPARγ/AKT pathway (Figure 1).¹⁶ On the other hand, PPARγ-induced adiponectin has been shown to attenuate excessive cytosolic Ca²⁺ and inhibit the subsequent mitochondria-dependent apoptosis by enhancing uptake of cytosolic Ca²⁺ into the sarcoplasmic reticulum in a sphingosine 1-phosphate/calmodulin kinase II signaling-dependent manner (Figure 1).¹⁰³ Furthermore, a recent study has demonstrated that antiapoptotic effects of PIO (5 and 10/kg/d for 7 days, orally, in rats) were associated with PPARγ-mediated enhanced activation of ERK,²² which attenuated cardiomyocyte apoptosis and myocardial infarct size through not only suppressing pro-apoptotic proteins (eg, B cell leukemia/lymphoma 2 [BCL-2]/BCL-XL-associated death promoter and BCL-2-associated X protein) but also stimulating the COX-2/prostaglandin E₂ pathway (Figure 1).^17,22

More interestingly, the natural PPARγ ligands, 15d-PGJ2 (0.5 mg/kg, intraperitoneally, in rats) was further found to result in antiapoptosis effects through promoting heat shock factor 1 binding to target genes that encoded heat shock proteins 70,¹¹ whereas PIO (10 mg/kg/d for 3 days, intraperitoneally, in PPARγ-knockout mice) contributed to anti-apoptosis effects through activating AKT and increasing expression of COX-2.¹⁰⁴ These observations suggest that antiapoptosis effects of PPARγ ligands can rely on additional PPARγ-independent mechanisms.

Failures of PPARγ Ligands in Cardioprotection

Notably, in contrast to general cardioprotective effects described above, PPARγ ligands have paradoxically failed to attenuate myocardial I/R injury in some studies. As shown by Xu et al, treatment with RSG (3 mg/kg/d for 8 weeks, orally, in pigs) has led to no significant effect on attenuating myocardial I/R injury, which was hypothetically attributed to the less severity of myocardial ischemia and suggested that the cardioprotective effects of RSG possibly associated with high severity of myocardial ischemia.¹⁰⁵

Even, possibly through a PPARγ-independent mechanism, acute preperfusion with high-dose troglitazone (at a mean myocardial concentration of 7.5 μg/g, in pigs) resulted in no attenuated myocardial I/R injury but increased susceptibility of cardiomyocyte to ventricular fibrillation, which was associated with ion channel dysfunction.¹⁰⁶ Similarly, another experiment, which was performed in isolated mice hearts and contained preperfusion with RSG (10 and 30 μM for 24 hours), led to enhanced oxidative stress and mitochondrial dysfunction after I/R, attributed to PPARγ-independent suppression on superoxide dismutase and inhibition on complexes I and IV in mitochondria.¹⁰⁷ Those results suggest that some PPARγ-independent pathways, at least in part, contribute to failures of PPARγ ligands in cardioprotection. It is possible that the higher risk of frustrated cardioprotection is associated with high dosage or concentrations of PPARγ ligands, which drive unexpected signaling pathways against cardioprotective effects of PPARγ.

Conclusion

As studies exploring the role of PPARγ in myocardial I/R injury have accumulated, a wide array of biological functions of PPARγ in cardioprotection during I/R have emerged. These cardioprotective effects of PPARγ, including attenuating oxidative stress, inhibiting inflammatory responses, improving glucose and lipid metabolism, and antagonizing apoptosis, suggest that PPARγ is a promising therapeutic target for ameliorating myocardial I/R injury. The mechanisms underlying these pleiotropic effects form a complex network involving regulation on target gene expression, influence on other transcription factors, and modulation on kinase signaling pathways, which interactively decrease cardiomyocyte damage in I/R.

However, although cardioprotective effects of PPARγ are demonstrated in plenty of experimental studies and human trails, regrettable failures of treatment with PPARγ synthetic ligands in cardioprotection have been reported, which are possibly associated with some PPARγ-independent pathways or adverse side effects of PPARγ activation. In order to prevent these negative effects of PPARγ synthetic ligands, further studies probing into more detailed elucidation of both PPARγ-dependent and PPARγ-independent mechanisms are required. Advances in more detailed clarification of molecular mechanisms will promote to develop PPARγ-dependent treatment strategies for alleviating myocardial I/R injury.

Footnotes

Author Contributions

Chong-Bin Zhong, Xi Chen, and Xu-Yue Zhou contributed equally to this article.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was funded by the National Natural Science Foundation of China (No: 81400190).

References

Writing Group Members; Mozaffarian

Benjamin

. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation. 2016;133(4):e38–e360.

Yellon

Hausenloy

. Myocardial reperfusion injury. N Engl J Med. 2007;357(11):1121–1135.

Heusch

Libby

Gersh

. Cardiovascular remodelling in coronary artery disease and heart failure. Lancet. 2014;383(9932):1933–1943.

Yingzhong

Lin

Chunbin

. Clinical effects of cyclosporine a on reperfusion injury in myocardial infarction: a meta-analysis of randomized controlled trials. Springerplus. 2016;5(1):1117.

Ricote

Glass

. PPARs and molecular mechanisms of transrepression. Biochim Biophys Acta. 2007;1771(8):926–935.

Shen

Sun

. Pioglitazone inhibits high glucose-induced expression of receptor for advanced glycation end products in coronary artery smooth muscle cells. Mol Med Rep. 2015;11(4):2601–2607.

Antonopoulos

Margaritis

Verheule

. Mutual regulation of epicardial adipose tissue and myocardial redox state by PPAR-γ/adiponectin signalling. Circ Res. 2016;118(5):842–855.

Kim

Park

Song

. The PPARγ agonist protects cardiomyocytes from oxidative stress and apoptosis via thioredoxin overexpression. Biosci Biotechnol Biochem. 2012;76(12):2181–2187.

Kataoka

Yagi

Kokubu

Kasahara

Abe

Otsuka

. Effect of pretreatment with pioglitazone on reperfusion injury in diabetic patients with acute myocardial infarction. Circ J. 2011;75(8):1968–1974.

10.

Nakano

Matoba

Tokutome

. Nanoparticle-mediated delivery of irbesartan induces cardioprotection from myocardial ischemia-reperfusion injury by antagonizing monocyte-mediated inflammation. Sci Rep. 2016;6:29601.

11.

Zingarelli

Hake

Mangeshkar

. Diverse cardioprotective signaling mechanisms of peroxisome proliferator-activated receptor-gamma ligands, 15-deoxy-Delta12, 14-prostaglandin J2 and ciglitazone, in reperfusion injury: role of nuclear factor-kappaB, heat shock factor 1, and Akt. Shock. 2007;28(5):554–563.

12.

Morrison

Yan

Tong

. Acute rosiglitazone treatment is cardioprotective against ischemia-reperfusion injury by modulating AMPK, Akt, and JNK signaling in nondiabetic mice. Am J Physiol Heart Circ Physiol. 2011;301(3):H895–H902.

13.

Liu

Liang

Liu

Cai

Gao

. Intervention of rosiglitazone on myocardium Glut-4 mRNA expression during ischemia-reperfusion injury in cardio-pulmonary bypass in dogs. Mol Cell Biochem. 2013;373(1-2):279–284.

14.

Yue

Bao

. Rosiglitazone treatment in Zucker diabetic fatty rats is associated with ameliorated cardiac insulin resistance and protection from ischemia/reperfusion-induced myocardial injury. Diabetes. 2005;54(2):554–562.

15.

Khandoudi

Delerive

Berrebi-Bertrand

Buckingham

Staels

Bril

. Rosiglitazone, a peroxisome proliferator-activated receptor-gamma, inhibits the Jun NH(2)-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury. Diabetes. 2002;51(5):1507–1514.

16.

Taniguchi

Ooie

Takahashi

. Pioglitazone but not glibenclamide improves cardiac expression of heat shock protein 72 and tolerance against ischemia/reperfusion injury in the heredity insulin-resistant rat. Diabetes. 2006;55(8):2371–2378.

17.

Xiao

Yuhki

Hara

. Prostaglandin E2 protects the heart from ischemia-reperfusion injury via its receptor subtype EP4. Circulation. 2004;109(20):2462–2468.

18.

Rinaldi

Di Filippo

Capuano

. Adiponectin elevation by telmisartan ameliorates ischaemic myocardium in Zucker diabetic fatty rats with metabolic syndrome. Diabetes Obes Metab. 2012;14(4):320–328.

19.

Zhang

Zhan

Chen

. Pharmacological activation of PPAR gamma ameliorates vascular endothelial insulin resistance via a non-canonical PPAR gamma-dependent nuclear factor-kappa B trans-repression pathway. Eur J Pharmacol. 2015;754:41–51.

20.

Wang

Zhang

. Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) through NF-kappaB/Brg1 and TGF-beta1 pathways attenuates cardiac remodeling in pressure-overloaded rat hearts. Cell Physiol Biochem. 2015;35(3):899–912.

21.

Qian

Chen

Birnbaum

Nanhwan

Bajaj

. Aleglitazar, a balanced dual PPARα and -γ agonist, protects the heart against ischemia-reperfusion injury. Cardiovasc Drugs Ther. 2016;30(2):129–141.

22.

Wang

Zhu

. Pioglitazone attenuates myocardial ischemia-reperfusion injury via up-regulation of ERK and COX-2. Biosci Trends. 2012;6(6):325–332.

23.

Bulluck

Yellon

Hausenloy

. Reducing myocardial infarct size: challenges and future opportunities. Heart. 2016;102(5):341–348.

24.

Kurian

Rajagopal

Vedantham

Rajesh

. The role of oxidative stress in myocardial ischemia and reperfusion injury and remodeling: revisited. Oxid Med Cell Longev. 2016;2016:1656450.

25.

Meyer

Andre

Kleindienst

. Carbon monoxide increases inducible NOS expression that mediates CO-induced myocardial damage during ischemia-reperfusion. Am J Physiol Heart Circ Physiol. 2015;308(7):H759–H767.

26.

Park

Kim

. Protective effects of peroxiredoxin on hydrogen peroxide induced oxidative stress and apoptosis in cardiomyocytes. Korean Circ J. 2012;42(1):23–32.

27.

Zhang

. Protective effect of sevoflurane postconditioning against cardiac ischemia/reperfusion injury via ameliorating mitochondrial impairment, oxidative stress and rescuing autophagic clearance. PLoS One. 2015;10(8):e0134666.

28.

. IL-23 promotes myocardial I/R injury by increasing the inflammatory responses and oxidative stress reactions. Cell Physiol Biochem. 2016;38(6):2163–2172.

29.

Liu

Wang

. Inflammation and inflammatory cells in myocardial infarction and reperfusion injury: a double-edged sword. Clin Med Insights Cardiol. 2016;10:79–84.

30.

Chen

Zhang

Wei

Ren

Gao

. Mechanism of TLR-4/NF-kappaB pathway in myocardial ischemia reperfusion injury of mouse. Asian Pac J Trop Med. 2016;9(5):503–507.

31.

Van der Heiden

Cuhlmann

Luong le

Zakkar

Evans

. Role of nuclear factor kappaB in cardiovascular health and disease. Clin Sci (Lond). 2010;118(10):593–605.

32.

Wang

Peng

. Rabbit sera containing compound Danshen dripping pill attenuate leukocytes adhesion to TNF-alpha—activated human umbilical vein endothelial cells by suppressing endothelial ICAM-1 and VCAM-1 expression through NF-kappaB signaling pathway. J Cardiovasc Pharmacol. 2014;63(4):323–332.

33.

Zhou

. Neutrophil extracellular traps in ischemia-reperfusion injury-induced myocardial no-reflow: therapeutic potential of DNase-based reperfusion strategy. Am J Physiol Heart Circ Physiol. 2015;308(5):H500–H509.

34.

Margaritis

Antonopoulos

Digby

. Interactions between vascular wall and perivascular adipose tissue reveal novel roles for adiponectin in the regulation of endothelial nitric oxide synthase function in human vessels. Circulation. 2013;127(22):2209–2221.

35.

Liang

Cai

Niu

. Cardiac glucose uptake and suppressed expression/translocation of myocardium glucose transport-4 in dogs undergoing ischemia-reperfusion. Exp Biol Med (Maywood). 2008;233(9):1142–1148.

36.

Kok

Brindley

. Myocardial fatty acid metabolism and lipotoxicity in the setting of insulin resistance. Heart Fail Clin. 2012;8(4):643–661.

37.

Liu

Chu

. The high-fat diet induces myocardial fibrosis in the metabolically healthy obese minipigs-the role of ER stress and oxidative stress. Clin Nutr. 2017;36(3):760–767.

38.

Bosma

Dapito

Drosatos-Tampakaki

. Sequestration of fatty acids in triglycerides prevents endoplasmic reticulum stress in an in vitro model of cardiomyocyte lipotoxicity. Biochim Biophys Acta. 2014;1841(12):1648–1655.

39.

Chen

Dong

. Apoptosis and autophagy contribute to gender difference in cardiac ischemia-reperfusion induced injury in rats. Life Sci. 2013;93(7):265–270.

40.

Yang

Guo

Zhang

. Hypothermia attenuates ischemia/reperfusion-induced endothelial cell apoptosis via alterations in apoptotic pathways and JNK signaling. FEBS Lett. 2009;583(15):2500–2506.

41.

Mattiazzi

Argenziano

Aguilar-Sanchez

Mazzocchi

Escobar

. Ca2+ Sparks and Ca2+ waves are the subcellular events underlying Ca2+ overload during ischemia and reperfusion in perfused intact hearts. J Mol Cell Cardiol. 2015;79:69–78.

42.

Liu

Tao

Song

Liu

Shi

. Panax quinquefolium saponin attenuates cardiomyocyte apoptosis and opening of the mitochondrial permeability transition pore in a rat model of ischemia/reperfusion. Cell Physiol Biochem. 2014;34(4):1413–1426.

43.

Kadivar

Heidari Khoei

Hassanpour

. Peroxisome proliferator-activated receptors (PPARα, PPARγ and PPARβ/δ) gene expression profile on ram spermatozoa and their relation to the sperm motility. Vet Res Forum. 2016;7(1):27–34.

44.

Tjokroprawiro

. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer). Acta Med Indones. 2006;38(3):160–166.

45.

Kim

Zhelyabovska

Liu

Yang

. Generation of an inducible, cardiomyocyte-specific transgenic mouse model with PPAR beta/delta overexpression. Methods Mol Biol. 2013;952:57–65.

46.

Liang

. Identification, organ expression and ligand-dependent expression levels of peroxisome proliferator activated receptors in grass carp (Ctenopharyngodon idella). Comp Biochem Physiol C Toxicol Pharmacol. 2012;155(2):381–388.

47.

Wang

Yang

Han

. Peroxisome proliferator-activated receptor gamma in malignant diseases. Crit Rev Oncol Hematol. 2006;58(1):1–14.

48.

Sundvold

Lien

. Identification of a novel peroxisome proliferator-activated receptor (PPAR) gamma promoter in man and transactivation by the nuclear receptor RORalpha1. Biochem Biophys Res Commun. 2001;287(2):383–390.

49.

Fajas

Fruchart

Auwerx

. PPARgamma3 mRNA: a distinct PPARgamma mRNA subtype transcribed from an independent promoter. FEBS Lett. 1998;438(1-2):55–60.

50.

Sharma

Monga

Singh

Datta

Singh

. Ovary-specific novel peroxisome proliferator activated receptors-gamma transcripts in buffalo. Gene. 2012;504(2):245–252.

51.

Tautenhahn

Brune

von Knethen

. Activation-induced PPARgamma expression sensitizes primary human T cells toward apoptosis. J Leukoc Biol. 2003;73(5):665–672.

52.

Gayet

Leray

Saito

Siliart

Nguyen

. The effects of obesity-associated insulin resistance on mRNA expression of peroxisome proliferator-activated receptor-gamma target genes, in dogs. Br J Nutr. 2007;98(3):497–503.

53.

Lee

Kao

Chen

Huang

Hsiao

Chen

. Peroxisome proliferator-activated receptors modulate cardiac dysfunction in diabetic cardiomyopathy. Diabetes Res Clin Pract. 2013;100(3):330–339.

54.

Fliegner

Westermann

Riad

. Up-regulation of PPARgamma in myocardial infarction. Eur J Heart Fail. 2008;10(1):30–38.

55.

Hasegawa

Okada

Okita

Pinsky

. Antioxidant properties of pioglitazone limit nicotinamide adenine dinucleotide phosphate hydrogen oxidase and augment superoxide dismutase activity in cardiac allotransplantation. J Heart Lung Transplant. 2011;30(10):1186–1196.

56.

Bagi

Koller

Kaley

. PPARgamma activation, by reducing oxidative stress, increases NO bioavailability in coronary arterioles of mice with type 2 diabetes. Am J Physiol Heart Circ Physiol. 2004;286(2):H742–H748.

57.

Yasuda

Kobayashi

Iwasa

. Antidiabetic drug pioglitazone protects the heart via activation of PPAR-gamma receptors, PI3-kinase, Akt, and eNOS pathway in a rabbit model of myocardial infarction. Am J Physiol Heart Circ Physiol. 2009;296(5):H1558–H1565.

58.

Zeng

Wen

. Telmisartan protects against microvascular dysfunction during myocardial ischemia/reperfusion injury by activation of peroxisome proliferator-activated receptor gamma. BMC Cardiovasc Disord. 2013;13:39.

59.

Marion-Letellier

Savoye

Ghosh

. Fatty acids, eicosanoids and PPAR gamma. Eur J Pharmacol. 2016;785:44–49.

60.

Vangaveti

Shashidhar

Rush

. Hydroxyoctadecadienoic acids regulate apoptosis in human THP-1 cells in a PPARγ-dependent manner. Lipids. 2014;49(12):1181–1192.

61.

Yan

Furumura

Numata

. Various peroxisome proliferator-activated receptor (PPAR)-γ agonists differently induce differentiation of cultured human keratinocytes. Exp Dermatol. 2015;24(1):62–65.

62.

Makita

Abiko

Naganuma

Moriai

Nakamura

. Potential effects of angiotensin II receptor blockers on glucose tolerance and adiponectin levels in hypertensive patients. Cardiovasc Drugs Ther. 2007;21(4):317–318.

63.

Zhang

Shang

Jin

. Cardiac protective effects of irbesartan via the PPAR-gamma signaling pathway in angiotensin-converting enzyme 2-deficient mice. J Transl Med. 2013;11:229.

64.

Wang

Liu

Zou

Shen

. Effect of GCP-02, a PPARalpha/gamma dual activator, on glucose and lipid metabolism in insulin-resistant mice. Eur J Pharmacol. 2008;580(1-2):277–283.

65.

Liu

Lambert

Leesnitzer

. Identification of a series of PPAR gamma/delta dual agonists via solid-phase parallel synthesis. Bioorg Med Chem Lett. 2001;11(22):2959–2962.

66.

Gross

Staels

. PPAR agonists: multimodal drugs for the treatment of type-2 diabetes. Best Pract Res Clin Endocrinol Metab. 2007;21(4):687–710.

67.

Khazaei

Salehi

. Myocardial capillary density in normal and diabetic male rats: Effect of bezafibrate. Res Pharm Sci. 2013;8(2):119–123.

68.

Davidoff

Mason

Davidson

. Sucrose-induced cardiomyocyte dysfunction is both preventable and reversible with clinically relevant treatments. Am J Physiol Endocrinol Metab. 2004;286(5):E718–E724.

69.

Ning

. In vitro and in vivo characterizations of chiglitazar, a newly identified PPAR pan-agonist. PPAR Res. 2012;2012:546548.

70.

Ceolotto

Gallo

Papparella

. Rosiglitazone reduces glucose-induced oxidative stress mediated by NAD(P)H oxidase via AMPK-dependent mechanism. Arterioscler Thromb Vasc Biol. 2007;27(12):2627–2633.

71.

Brown

Plutzky

. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation. 2007;115(4):518–533.

72.

Ding

Qin

. Cardiac peroxisome proliferator-activated receptor gamma is essential in protecting cardiomyocytes from oxidative damage. Cardiovasc Res. 2007;76(2):269–279.

73.

Ravingerova

Adameova

Carnicka

. The role of PPAR in myocardial response to ischemia in normal and diseased heart. Gen Physiol Biophys. 2011;30(4):329–341.

74.

Majdalawieh

. Regulation of IkappaBalpha function and NF-kappaB signaling: AEBP1 is a novel proinflammatory mediator in macrophages. Mediators Inflamm. 2010;2010:823821.

75.

Zhang

Foster

Sun

. Restraint stress induces lymphocyte reduction through p53 and PI3K/NF-kappaB pathways. J Neuroimmunol. 2008;200(1-2):71–76.

76.

Hobson

Hake

O’Connor

. Conditional deletion of cardiomyocyte peroxisome proliferator-activated receptor gamma enhances myocardial ischemia-reperfusion injury in mice. Shock. 2014;41(1):40–47.

77.

Majdalawieh

. PPARgamma1 and LXRalpha face a new regulator of macrophage cholesterol homeostasis and inflammatory responsiveness, AEBP1. Nucl Recept Signal. 2010;8:e004.

78.

Kone

. The STAT3 DNA-binding domain mediates interaction with NF-kappaB p65 and inducible nitric oxide synthase transrepression in mesangial cells. J Am Soc Nephrol. 2004;15(3):585–591.

79.

Kurtz

Capobianco

Martinez

Roberti

Arany

Jawerbaum

. PPAR ligands improve impaired metabolic pathways in fetal hearts of diabetic rats. J Mol Endocrinol. 2014;53(2):237–246.

80.

Ahmadian

Suh

Hah

. PPARγ signaling and metabolism: the good, the bad and the future. Nat Med. 2013;19(5):557–566.

81.

Kuo

Chen

Niu

Cheng

. Activation of receptors δ (PPARδ) by agonist (GW0742) may enhance lipid metabolism in heart both in vivo and in vitro. Horm Metab Res. 2013;45(12):880–886.

82.

Klempfner

Goldenberg

Fisman

. Comparison of statin alone versus bezafibrate and statin combination in patients with diabetes mellitus and acute coronary syndrome. Am J Cardiol. 2014;113(1):12–16.

83.

Delerive

De Bosscher

Vanden Berghe

Fruchart

Haegeman

Staels

. DNA binding-independent induction of IkappaBalpha gene transcription by PPARalpha. Mol Endocrinol. 2002;16(5):1029–1039.

84.

Xiao

Brown

Chen

Ren

Zhao

. Peroxisome proliferator-activated receptors gamma and alpha agonists stimulate cardiac glucose uptake via activation of AMP-activated protein kinase. J Nutr Biochem. 2010;21(7):621–626.

85.

Shi

Hon

Evans

. The peroxisome proliferator-activated receptor delta, an integrator of transcriptional repression and nuclear receptor signaling. Proc Natl Acad Sci U S A. 2002;99(5):2613–2618.

86.

Gustafsson

Knight

Palmer

. Ligand modulated antagonism of PPARgamma by genomic and non-genomic actions of PPARdelta. PLoS One. 2009;4(9):e7046.

87.

Haemmerle

Moustafa

Woelkart

. ATGL-mediated fat catabolism regulates cardiac mitochondrial function via PPAR-α and PGC-1. Nat Med. 2011;17(9):1076–1085.

88.

Moreno

Lombardi

Silvestri

. PPARs: nuclear receptors controlled by, and controlling, nutrient handling through nuclear and cytosolic signaling. PPAR Res. 2010;2010:pii: 435689.

89.

Riahi

Cohen

Shamni

Sasson

. Signaling and cytotoxic functions of 4-hydroxyalkenals. Am J Physiol Endocrinol Metab. 2010;299(6):E879–E886.

90.

Gao

Liu

. TNF-α antagonism ameliorates myocardial ischemia-reperfusion injury in mice by upregulating adiponectin. Am J Physiol Heart Circ Physiol. 2015;308(12):H1583–H1591.

91.

Fordyce

Gersh

Stone

Granger

. Novel therapeutics in myocardial infarction: targeting microvascular dysfunction and reperfusion injury. Trends Pharmacol Sci. 2015;36(9):605–616.

92.

Chen

Vigueira

Chambers

. Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor γ-sparing thiazolidinedione. J Biol Chem. 2012;287(28):23537–23548.

93.

Zhang

Liu

. AMPK-regulated and Akt-dependent enhancement of glucose uptake is essential in ischemic preconditioning-alleviated reperfusion injury. PLoS One. 2013;8(7):e69910.

94.

Wensley

Salaveria

Bulmer

Donner

du Toit

. Myocardial structure, function and ischaemic tolerance in a rodent model of obesity with insulin resistance. Exp Physiol. 2013;98(11):1552–1564.

95.

Zhang

Tang

Liang

. [Influence of siRNA-mediated PPARgamma gene knockdown on insulin resistance induced by myocardial ischemia-reperfusion in rats]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2013;44(6):891–896.

96.

Haffar

Berube-Simard

Bousette

. Impaired fatty acid oxidation as a cause for lipotoxicity in cardiomyocytes. Biochem Biophys Res Commun. 2015;468(1-2):73–78.

97.

Badeau

Honka

Lautamaki

. Systemic metabolic markers and myocardial glucose uptake in type 2 diabetic and coronary artery disease patients treated for 16 weeks with rosiglitazone, a PPARγ agonist. Ann Med. 2014;46(1):18–23.

98.

Huss

Kelly

. Nuclear receptor signaling and cardiac energetics. Circ Res. 2004;95(6):568–578.

99.

Verschuren

Wielinga

Kelder

. A systems biology approach to understand the pathophysiological mechanisms of cardiac pathological hypertrophy associated with rosiglitazone. BMC Med Genomics. 2014;7:35.

100.

Nissen

Wolski

. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457–2471.

101.

Milano

Morel

Bonny

. A peptide inhibitor of c-Jun NH2-terminal kinase reduces myocardial ischemia-reperfusion injury and infarct size in vivo. Am J Physiol Heart Circ Physiol. 2007;292(4):H1828–H1835.

102.

Qin

Cai

. Mitochondrial JNK activation triggers autophagy and apoptosis and aggravates myocardial injury following ischemia/reperfusion. Biochim Biophys Acta. 2015;1852(2):262–270.

103.

Yan

Zhang

. Adiponectin regulates SR Ca(2+) cycling following ischemia/reperfusion via sphingosine 1-phosphate-CaMKII signaling in mice. J Mol Cell Cardiol. 2014;74:183–192.

104.

Birnbaum

Long

Qian

Perez-Polo

. Pioglitazone limits myocardial infarct size, activates Akt, and upregulates cPLA2 and COX-2 in a PPAR-gamma-independent manner. Basic Res Cardiol. 2011;106(3):431–446.

105.

Gen

. PPAR-gamma activation fails to provide myocardial protection in ischemia and reperfusion in pigs. Am J Physiol Heart Circ Physiol. 2005;288(3):H1314–H1323.

106.

Greyson

. Deleterious effects of acute treatment with a peroxisome proliferator-activated receptor-gamma activator in myocardial ischemia and reperfusion in pigs. Diabetes. 2003;52(5):1187–1194.

107.

Tao

Xiong

. Rosiglitazone causes cardiotoxicity via peroxisome proliferator-activated receptor gamma-independent mitochondrial oxidative stress in mouse hearts. Toxicol Sci. 2014;138(2):468–481.

The Role of Peroxisome Proliferator-Activated Receptor γ in Mediating Cardioprotection Against Ischemia/Reperfusion Injury

Abstract

Keywords

Introduction

Mechanisms of Myocardial I/R Injury

An Overview of PPARγ

Peroxisome Proliferator-Activated Receptor γ as a Nuclear Receptor

The Ligands of PPARγ

Transcriptional Transactivation of PPARγ

Transcriptional Transrepression of PPARγ

Complementary Effects and Interactions Between PPARs

Peroxisome Proliferator-Activated Receptor γ in Cardioprotection

Peroxisome Proliferator-Activated Receptor γ and Oxidative Stress

Peroxisome Proliferator-Activated Receptor γ and Inflammatory Responses

Peroxisome Proliferator-Activated Receptor γ and Cardiac Glucose and Lipid Metabolism

Peroxisome Proliferator-Activated Receptor γ and Cardiac Apoptosis

Failures of PPARγ Ligands in Cardioprotection

Conclusion

Footnotes

Author Contributions

Declaration of Conflicting Interests

Funding

References